iC9-CAR.B7-H3 T Cell Therapy (Unc Lineberger Comprehensive Cancer Center/Bellicum Pharmaceuticals)

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameiC9-CAR.B7-H3 T Cell Therapy (Unc Lineberger Comprehensive Cancer Center/Bellicum Pharmaceuticals)
Drug Alias NameAutologous CAR-T Cells Targeting B7-H3 (Unc Lineberger Comprehensive Cancer Center/Bellicum Pharmaceuticals)B7H3 CAR T cell therapy (Unc Lineberger Comprehensive Cancer Center/Bellicum Pharmaceuticals)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionT lymphocyte replacementsAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsOvarian NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals IncUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A